Guangdong Biobank Cohort (GDBC) study

作者：Yong-Qiao He, Wen-Qiong Xue, Hua Diao, Jiyun Zhan, Ming-Fang Ji, Da-Wei Yang, Yi Zhao, Chang-Mi Deng, Ziyi Wu, Ting Zhou, Ying Liao, Mei-Qi Zheng, Wen-Li Zhang, Yi-Jing Jia, Lei-Lei Yuan, Lu-Ting Luo, Dan‐Hua Li, Tong-Min Wang, Xia‐Ting Tong, Yan Ni Du, Ling-Ling Tang, Jing-Wen Huang, Chang-ling Huang, Zhi-Yang Zhao, Yan-Xia Wu, Lian-jing Cao, Si-Qi Dong, Fang Wang, Cheng-Tao Jiang, Ruo-Wen Xiao, Wen-Bin Zhang, Xueyin Chen, Qiao-Ling Wang, Qiao-Yun Liu, Yue-Ze Zhao, Cao-Li Tang, Lin Ma, Xiaohui Zheng, Pei-Fen Zhang, Xi-Zhao Li, Shao-Dan Zhang, Ye-Zhu Hu, Yu Xia, Biao-Hua Wu, Fu-gui Li, Jian-Hua Wu, Bi-Sen Deng, Xuejun Liang, Wei-Hua Jia · 发表于：European Journal of Epidemiology · 年份：2026 · DOI：10.1007/s10654-025-01320-y · 研究领域：Genetic Associations and Epidemiology、Nutrition, Genetics, and Disease、Cardiovascular Health and Risk Factors

The global rise of non-communicable diseases (NCDs) presents an urgent public health challenge, particularly in regions undergoing rapid economic and demographic transitions. Guangdong Province, China's most populous and economically advanced region, is experiencing a substantial and accelerating burden of NCDs. However, large-scale, population-based cohorts from this region remain scarce, limiting insights into region-specific disease determinants and prevention strategies. The Guangdong Biobank Cohort (GDBC) was established in 2017, enrolling 35,081 participants aged 40-84 years from urban and rural areas of Zhongshan City in the Pearl River Delta. At baseline, comprehensive data on 346 variables-including lifestyle, environmental exposures, medical histories, physical examinations, and laboratory profiles-were collected via a cloud-based member management information system (MMIS), alongside blood and saliva samples for biobanking. A sub-cohort underwent genome-wide genotyping (N = 2,530) and oral microbiome profiling via 16 S rRNA sequencing (N = 2,049). During dynamic follow-up, 44.2% (N = 15,499) completed Phase I resurvey with repeated measurements and updated biospecimens. Disease outcomes, including hypertension, diabetes, and cancer, were ascertained through active surveillance and regional registry linkage until December 2023. Baseline prevalence of hypertension, diabetes, and cancer was 25.3%, 8.0%, and 3.6%, respectively. Over follow-up, 1,767 hypertension cases,...